These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 35527415

  • 1. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
    Wang X, Pan SL, DU ZH, Ji ZX, Luo G, Sun HX, Ma SJ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr 15; 24(4):399-404. PubMed ID: 35527415
    [Abstract] [Full Text] [Related]

  • 2. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
    Huang XB, Zhao S, Liu ZY, Xu YY, Deng F.
    Ann Med; 2023 Apr 15; 55(2):2264315. PubMed ID: 37870383
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
    Clin Rheumatol; 2023 Jan 15; 42(1):167-177. PubMed ID: 36129563
    [Abstract] [Full Text] [Related]

  • 4. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Jan 15; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 5. Risk factors of immunoglobulin resistance and coronary complications in children with Kawasaki disease.
    Berdej-Szczot E, Małecka-Tendera E, Gawlik T, Firek-Pędras M, Szydłowski L, Gawlik A.
    Kardiol Pol; 2017 Jan 15; 75(3):261-266. PubMed ID: 27995598
    [Abstract] [Full Text] [Related]

  • 6. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 15; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

  • 7. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Aug 15; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

  • 8. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
    Li W, Zhang L, Wang Z, He X, Lin H, Wang Y, Yuan J, Xie X, Zhang X, Qin Y, Huang P.
    Int J Clin Pract; 2022 Aug 15; 2022():2726686. PubMed ID: 35989868
    [Abstract] [Full Text] [Related]

  • 9. Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease.
    Lu Y, Chen T, Wen Y, Si F, Wu X, Yang Y.
    BMC Pediatr; 2021 Sep 16; 21(1):406. PubMed ID: 34530763
    [Abstract] [Full Text] [Related]

  • 10. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 16; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 11. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease.
    Türkuçar S, Yıldız K, Acarı C, Dundar HA, Kır M, Ünsal E.
    Turk J Pediatr; 2020 May 16; 62(1):1-9. PubMed ID: 32253860
    [Abstract] [Full Text] [Related]

  • 12. Risk Factors for Coronary Artery Aneurysm in a Chinese Pediatric Population with Kawasaki Disease at Low Risk of Intravenous Immunoglobulin Resistance: A Retrospective Cohort Study.
    Liu J, Su D, Yuan P, Ye B, Qin S, Pang Y.
    Cardiology; 2023 May 16; 148(5):457-468. PubMed ID: 37231847
    [Abstract] [Full Text] [Related]

  • 13. Coronary artery status of patients with transient fever 24-36 h after first IVIG infusion did not differ from that seen in responsive patients.
    Baek JS, Yu JJ, Kim MJ, You J, Jun HO, Kim YH, Ko JK.
    Pediatr Rheumatol Online J; 2018 Dec 29; 16(1):83. PubMed ID: 30594188
    [Abstract] [Full Text] [Related]

  • 14. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 29; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 15. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM, Silverman ED, McCrindle BW, Yeung RS.
    J Pediatr; 2002 Apr 29; 140(4):450-5. PubMed ID: 12006960
    [Abstract] [Full Text] [Related]

  • 16. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M, Shiozawa Y, Kagawa J.
    Pediatr Cardiol; 2015 Aug 29; 36(6):1159-65. PubMed ID: 25753685
    [Abstract] [Full Text] [Related]

  • 17. [Association of liver damage with coronary artery lesion and no response to intravenous immunoglobulin in the acute stage of Kawasaki disease].
    Hu HM, Chen XZ, Zhang YL, DU ZD.
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun 15; 24(6):681-686. PubMed ID: 35762436
    [Abstract] [Full Text] [Related]

  • 18. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Jun 15; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 19. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T, Michihata N, Aso S, Yoshikawa T, Saito K, Matsui H, Fushimi K, Yasunaga H.
    Eur J Pediatr; 2021 Nov 15; 180(11):3279-3286. PubMed ID: 33973071
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 15; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.